Clinical trials: Human Papillomavirus (HPV) Vaccines
Cervical Cancer, Genital Warts
Alternate Dosing Schedules Study for HPV Vaccine (ADS)
The purpose of this study was to determine if delayed dosing of recombinant human papillomavirus (HPV) quadrivalent (Types 6, 11, 16, and 18) vaccine in 9-18 year old girls elicited an equivalent immune response (geometric mean…
- Trial name
- ADS (NCT02280642)
- Testing
- Both 2nd and 3rd doses on time, 2nd dose late and 3rd dose on time, 2nd dose on time and 3rd dose late
- Where
- 3 sites in United States
- Volunteers
- 331 people, healthy volunteers welcome
- Sponsor
- Duke University
Cervical Cancer
Safety and Immunogenicity Study of Human Papilloma Virus Vaccine in Women Aged 9 to 30 and Men Aged 9 to 17
This study evaluates the safety of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in women of 9 to 30 years old and men of 9 to 17 years old and preliminarily explore the…
- Trial name
- NCT02888418
- Testing
- Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha)
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Beijing Chaoyang District Centre for Disease Control and Prevention
Cervical Intraepithelial Neoplasia, Cervical Cancer
The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female
The primary objective of this study is to evaluate the durability of protection of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine administered in females aged 18-45 years.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT04969445
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
- Where
- China
- Volunteers
- 647 people
- Sponsor
- Jun Zhang
Papillomavirus Infections
A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects
The purpose of this study is to evaluate the safety, tolerability, and the immunological effects of adeno-associated virus-like particle human papillomavirus (AAVLP-HPV) vaccine in healthy adults.
- Trial name
- NCT03929172
- Testing
- AAVLP-HPV
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- 2A Pharma AB
Human Papilloma Virus
Increasing Human Papillomavirus (HPV) Vaccine Uptake Via General Health Messaging
Background: Prevention of cervical cancer and genital warts could be achieved by immunization with the prophylactic human papillomavirus (HPV) vaccines commercially available. However, in the U.S.
- Trial name
- NCT03759236
- Testing
- Health Messaging via SMS, CDC Health Pamphlets
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Human Papilloma Virus (HPV) Vaccine
HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)
This intervention study will use parent-, provider-, and health center-level strategies to promote HPV vaccination among 11-17 year olds receiving care in 8 community health centers in Florida, will explore factors related to the…
- Trial name
- HPV MISTICS (NCT05677360)
- Testing
- HPV MISTICS -Provider Level, HPV MISTICS - Parent Level, HPV MISTICS- HPV Vaccine Champion Level
- Where
- United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Human Papilloma Virus (HPV) Vaccine
Knowledge, Attitude &Practice on Human Papilloma Virus Vaccination Among Healthcare Providers and General Population
Cervical cancer is caused by persistent infection with certain strains of the human papillomavirus (HPV), which is a very common virus transmitted through sexual activity.
- Trial name
- NCT06743880
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Assiut University
Cancer Survivor, Prevention of Human Papillomavirus Infection
Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors
This trial will comprehensively evaluate the human papillomavirus (HPV) vaccine in cancer survivors between 9 and 26 years of age by (1) determining the prevalence of HPV vaccine initiation among young cancer survivors, and (2)…
- Trial name
- NCT01492582
- Testing
- quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58), laboratory biomarker analysis, survey administration
- Where
- 5 sites in United States
- Volunteers
- 1,499 people
- Sponsor
- University of Alabama at Birmingham
Human Papillomavirus Infection
Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting
This is a randomized, open label trial of HPV (human papilloma virus) vaccine, comparing an on-time administration of the third dose with delayed administration of the third dose.
- Trial name
- NCT00572832
- Testing
- Quadrivalent human papillomavirus vaccine on-time administration, Quadrivalent human papillomavirus vaccine delayed administration
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Papillomavirus Infections
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
The purpose of this study is to evaluate the safety and tolerability of the Quadrivalent Human Papilloma Virus (HPV) vaccine in healthy females 9 to 15 years of age in India.
- Trial name
- NCT00380367
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Vulvar Cancer
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
The purpose of this study is to evaluate vaccine immunogenicity and how well the body tolerates V504 when given with Gardasil.
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT00551187
- Testing
- V504, Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus (HPV) Vaccine, Human Papillomavirus (HPV) Vaccines
Strengthening HPV Vaccination and Adolescent Health Research Program in Nigeria (SHARP)
The goal of this clinical trial is to learn whether adding adolescent health services to routine government health programs can increase Human Papillomavirus (HPV) vaccination coverage among 9-year-old girls and improve use of…
- Conditions
- Human Papillomavirus (HPV) Vaccine, Human Papillomavirus (HPV) Vaccines, Human Papillomavirus (HPV) Infections, Adolescent Health Services
- Trial name
- SHARP (NCT07200414)
- Testing
- Integrated Adolescent Health Package, Routine Government Health Services
- Where
- Nigeria
- Volunteers
- 12,654 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HPV Infections
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
A randomized, double-blind and placebo-controlled phase I study to evaluate the safety and immunogenicity of a 9-valent Human Papillomavirus (HPV) vaccine, administered intramuscularly according to a 0, 2, 6-month schedule in 9…
- Trial name
- NCT03900572
- Testing
- HPV Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Human Papillomavirus Infection
Comparative Effectiveness of System Interventions to Increase HPV Vaccine Receipt in FQHCs
UCLA and Northeast Valley Health Center (NEVHC), a large, multi-site Federally Qualified Health Center (FQHC), are partnering to address underutilization of the prophylactic HPV vaccine among underserved, ethnic minority…
- Trial name
- NCT03726151
- Testing
- Parent Reminders, Multicomponent clinic-system strategies, Combined Condition
- Where
- 7 sites in United States
- Volunteers
- 17,000 people
- Sponsor
- University of California, Los Angeles
Cervical Cancers, Vulvar Cancers
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™.
- Conditions
- Cervical Cancers, Vulvar Cancers, Vaginal Cancers, Genital Warts
- Trial name
- NCT01047345
- Testing
- V503
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
CIN - Cervical Intraepithelial Neoplasia, HPV
Multiple Human Papillomavirus Infections in the Development of CIN
Multiple infections of high-risk genotypes of Human Papillomavirus (HR-HPV) in patients with abnormal cervical cytological or histological findings are detectable in a percentage ranging from 20% to 50% of cases.
- Conditions
- CIN - Cervical Intraepithelial Neoplasia, HPV, HPV Vaccines
- Trial name
- HPV dysplasia (NCT06862102)
- Testing
- HPV vaccine
- Where
- Italy
- Volunteers
- 152 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Cervical Cancer
Acceptability and Feasibility of Human Papilloma Virus Vaccine
The overall program goal is to determine the Acceptability and Feasibility of introducing a population based Human Papilloma Virus (HPV) Vaccination programme and understanding the key individual and community factors that would…
- Trial name
- NCT01209338
- Testing
- Health education
- Where
- India
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Tata Memorial Hospital
Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases
Culturally Tailored HPV Psychoeducational Multimedia Intervention
Community members ages 18 - 45 years old from the El Paso, Texas, U.S.-Mexico Border Region will be recruited to compare psychoeducational multimedia interventions focused on the human papillomavirus (HPV).
- Conditions
- Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases, Intention, Adherence, Patient
- Trial name
- NCT06098690
- Testing
- Culturally Tailored Multimedia Psychoeducational HPV Intervention, General HPV Multimedia Psychoeducational Control Group
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Texas, El Paso
HPV Vaccine Acceptability
Impact of a School- and Primary Care-based Multicomponent Intervention on HPV Vaccination Acceptability
This study aims at evaluating the effectiveness, efficiency and implementation of a multicomponent intervention (components being applied in combination or alone) on the acceptability of HPV vaccine among French adolescents…
- Trial name
- PrevHPV (NCT04945655)
- Testing
- Adolescents and parents' education and motivation at school (component 1), General practitioners' training (component 2), Access to vaccination at school (component 3)
- Where
- France
- Volunteers
- 30,739 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
HIV Positive, Anal Condylomata
The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata
The primary objective of this pilot study is to evaluate the effect of the HPV vaccine Gardasil on anal condylomata recurrence and persistence rates in HIV positive patients.
- Conditions
- HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
- Trial name
- NCT00941889
- Testing
- Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Washington University School of Medicine